SAGA Diagnostics is a pioneering company focused on revolutionizing the early detection of Molecular Residual Disease (MRD) to personalize cancer treatment. Their unique MRD testing platform, based on proprietary hybrid technologies utilizing next-generation sequencing (NGS) and digital PCR, enables highly sensitive and specific detection of residual cancer following treatment. By leveraging tumor-specific structural variants to create a unique genetic fingerprint for each patient's cancer, SAGA Diagnostics provides oncologists, researchers, and drug developers with precise tools to monitor treatment response and detect disease early. Their liquid biopsy test is designed to continuously monitor a patient's cancer through simple blood draws, offering clarity and confidence at all stages of treatment. This innovative approach is helping improve cancer therapy decision-making and is a valuable partner for biopharma in accelerating drug development and commercialization efforts.
Cancer companion diagnostics β’ Circulating tumor DNA analysis β’ Tissue analysis β’ Actionable mutations β’ Mutation screening
July 4
Drive scientific engagement and clinical adoption of MRD testing in oncology for SAGA Diagnostics.
June 14
Design and implement backend systems for genomic diagnostics at SAGA Diagnostics. Join a fast-paced team focused on innovative solutions in the biotech field.
June 5
SAGA Diagnostics seeks an Account Executive to meet sales objectives in oncology. Primary focus on building relationships with healthcare providers in the West.
May 29
SAGA Diagnostics seeks an Oncology/MRD Account Executive to improve cancer diagnostics and monitoring in the Northeast.
May 29
Join SAGA Diagnostics as an Oncology/MRD Account Executive focused on personalized cancer diagnostics and sales in the Southeast.